IL308389A - Dosing regimens for acubactadine - Google Patents

Dosing regimens for acubactadine

Info

Publication number
IL308389A
IL308389A IL308389A IL30838923A IL308389A IL 308389 A IL308389 A IL 308389A IL 308389 A IL308389 A IL 308389A IL 30838923 A IL30838923 A IL 30838923A IL 308389 A IL308389 A IL 308389A
Authority
IL
Israel
Prior art keywords
ecubectedin
dosage regimens
regimens
dosage
Prior art date
Application number
IL308389A
Other languages
English (en)
Hebrew (he)
Inventor
Carmen Kahatt
Pilar Lardelli
Cristian Fernandez
Arturo Soto
Original Assignee
Pharma Mar Sa
Carmen Kahatt
Pilar Lardelli
Cristian Fernandez
Arturo Soto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa, Carmen Kahatt, Pilar Lardelli, Cristian Fernandez, Arturo Soto filed Critical Pharma Mar Sa
Publication of IL308389A publication Critical patent/IL308389A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL308389A 2021-05-19 2022-05-19 Dosing regimens for acubactadine IL308389A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21382455 2021-05-19
PCT/EP2022/063653 WO2022243482A1 (en) 2021-05-19 2022-05-19 Dosage regimens for ecubectedin

Publications (1)

Publication Number Publication Date
IL308389A true IL308389A (en) 2024-01-01

Family

ID=76197383

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308389A IL308389A (en) 2021-05-19 2022-05-19 Dosing regimens for acubactadine

Country Status (11)

Country Link
US (1) US20240277705A1 (cg-RX-API-DMAC7.html)
EP (1) EP4340841A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521122A (cg-RX-API-DMAC7.html)
KR (1) KR20240009437A (cg-RX-API-DMAC7.html)
CN (1) CN117295499A (cg-RX-API-DMAC7.html)
AU (1) AU2022277799A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218171A1 (cg-RX-API-DMAC7.html)
IL (1) IL308389A (cg-RX-API-DMAC7.html)
MX (1) MX2023013715A (cg-RX-API-DMAC7.html)
TW (1) TW202313039A (cg-RX-API-DMAC7.html)
WO (1) WO2022243482A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
WO2025228595A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
TW202547503A (zh) 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之pm14和拓樸異構酶i抑制劑的組合
WO2025228594A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
EP2786755A3 (en) * 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
WO2022243482A1 (en) 2022-11-24
MX2023013715A (es) 2024-03-26
TW202313039A (zh) 2023-04-01
CA3218171A1 (en) 2022-11-24
EP4340841A1 (en) 2024-03-27
AU2022277799A1 (en) 2023-12-21
CN117295499A (zh) 2023-12-26
US20240277705A1 (en) 2024-08-22
KR20240009437A (ko) 2024-01-22
JP2024521122A (ja) 2024-05-28

Similar Documents

Publication Publication Date Title
IL287004A (en) Dosage forms and regimens for amino acid compounds
IL289949A (en) Dosing regimens for oral complement factor d inhibitors
IL291452A (en) Dosage forms for tyk2 inhibitors
IL287132A (en) Abuse-resistant dosage forms that include asketamine
GB202020191D0 (en) Pharmaceutical compounds
GB202010409D0 (en) Pharmaceutical compounds
ZA201802816B (en) Melflufen dosage regimens for cancer
IL281968A (en) Dosage regimen for TFPI antagonists
GB202010408D0 (en) Pharmaceutical compounds
IL279214A (en) Therapeutic dosage regimens comprising adherent stromal cells
GB202104097D0 (en) Pharmaceutical compounds
IL315178A (en) Dosage regimen
IL308095A (en) Dosing regimens
GB202006819D0 (en) Dosage regimen
HK40108270A (zh) 依维替定的给药方案
GB202102602D0 (en) Pharmaceutical compounds
GB202015771D0 (en) Dosage regimen
GB202014116D0 (en) Dosage regimen
GB202006699D0 (en) Dosage regimen
GB202319534D0 (en) Dosage regimen
GB202306662D0 (en) Dosage regimen
HK40105571A (zh) Parp7抑制剂的剂量方案
GB201902454D0 (en) Dosage regimen
GB202213032D0 (en) Dosage regime
GB202212323D0 (en) Dosage regime